All In Biotech

NDA 020929 · Astrazeneca

Pulmicort Respules

Budesonide · Inhalation · Corticosteroid

Priority review

Last checked: Nov 20, 2026Latest source record: Sep 6, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Aug 8, 2000

Approved uses

3

Original approval plus efficacy supplements

Registered trials

592

206 Phase 3, 32 recruiting

FAERS reports

42,547

32,411 serious, 3,177 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 11, 2019.

PULMICORT RESPULES ® is an inhaled corticosteroid indicated for: • Maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age ( 1 ) Limitations of Use: Not indicated for the relief of acute bronchospasm ( 1 ) 1.1 Maintenance Treatment of Asthma PULMICORT RESPULES is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age. Limitations of Use : • PULMICORT RESPULES is NOT indicated for the relief of acute bronchospasm.

Mechanism: Budesonide is an anti-inflammatory corticosteroid that exhibits potent glucocorticoid activity and weak mineralocorticoid activity. In standard in vitro and animal models, budesonide has approximately a 200-fold higher affinity for the glucocorticoid receptor and a 1000-fold higher topical anti-inflammatory potency than cortisol (rat croton oil ear edema assay). As a measure of systemic activity, budesonide is 40 times more potent than cortisol when administered subcutaneously and 25 times more potent when administered orally in the rat thymus involution assay. The clinical significance of...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • PULMICORT RESPULES · BUDESONIDE 1MG/2ML · SUSPENSION, INHALATION · Prescription · TE AN
  • PULMICORT RESPULES · BUDESONIDE 0.25MG/2ML · SUSPENSION, INHALATION · Prescription · TE AN
  • PULMICORT RESPULES · BUDESONIDE 0.5MG/2ML · SUSPENSION, INHALATION · Prescription · TE AN

Clinical trials

Interventional ClinicalTrials.gov studies with "Budesonide" as an intervention, any sponsor and status, largest first.

All 592 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,994
  • dyspnoea4,876
  • off label use4,639
  • asthma3,791
  • fatigue2,641
  • condition aggravated2,522
  • headache2,477
  • diarrhoea2,412
  • cough2,387
  • pneumonia2,319
  • nausea2,151
  • wheezing2,124

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004161
2005230
2006219
2007434
2008576
2009570
2010549
2011563
2012822
2013840
20141,041
20151,402
20161,632
20171,742
20182,306
20193,015
20203,624
20213,765
20224,013
20233,995
20244,143
20254,049
20262,856

Recalls

2 FDA enforcement reports for this application.

  • Jan 11, 2013 · Class III · Terminated

    Does Not Meet Monograph: Budesonide may be slightly above or below the specification range.

  • Jan 11, 2013 · Class III · Terminated

    Does Not Meet Monograph: Budesonide may be slightly above or below the specification range.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,119 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.